Academic Highlights: Enhancing Treatment Response in Depression. [CME]
Philip T. Ninan, MD; Maurizio Fava, MD; and Kerry J. Ressler, MD, PhD
J Clin Psychiatry 2004;65(9):1269-1280
© Copyright 2017 Physicians Postgraduate Press, Inc.
To view this item, select one of the options below.
-
-
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
-
Subscribe
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
-
-
Activate
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
-
Sign in
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
-
Click here to login.
-
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
![First page of Academic Highlights: Enhancing Treatment Response in Depression. [CME]](/JCP/article/publishingimages/firstpages/v65n0917.jpg)
Click to enlarge page
Kerry J. Ressler, MD, PhD, opened with the statement that the symptoms of major depressive disorder can be viewed as a result of brain circuit dysfunction. Three classes of molecules involved in depressive symptoms include the monoamines, which regulate broad functioning of neural circuits; neuropeptides, which mediate behavior-specific components of neural circuits; and neurotrophins, which allow for plasticity of the brain and maintenance of neural circuits.